Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Up 1,340.3% in July

Key Points

• Chugai Pharmaceutical Co., Ltd. experienced a 1,340.3% increase in short interest from July 15 to July 31, reaching a total of 110,900 shares.
• The company's stock price is currently at $20.79, with a market capitalization of $68.42 billion and a PE ratio of 26.32.
• Chugai reported quarterly earnings of $0.20 EPS with revenues of $2.01 billion for the last quarter.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) saw a large increase in short interest in July. As of July 31st, there was short interest totaling 110,900 shares, anincreaseof1,340.3% from the July 15th total of 7,700 shares. Based on an average trading volume of 485,800 shares, the short-interest ratio is presently 0.2 days. Approximately0.0% of the shares of the stock are short sold. Approximately0.0% of the shares of the stock are short sold. Based on an average trading volume of 485,800 shares, the short-interest ratio is presently 0.2 days.

Chugai Pharmaceutical Price Performance

OTCMKTS CHGCY traded up $0.83 during trading hours on Tuesday, hitting $21.98. 258,804 shares of the company's stock traded hands, compared to its average volume of 149,349. Chugai Pharmaceutical has a 52-week low of $19.50 and a 52-week high of $31.26. The company has a market capitalization of $72.34 billion, a PE ratio of 27.82 and a beta of 0.65. The firm's 50-day moving average is $23.98 and its 200-day moving average is $24.68.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. The company had revenue of $2.01 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. Equities research analysts predict that Chugai Pharmaceutical will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.